Compare GMAB & RS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GMAB | RS |
|---|---|---|
| Founded | 1999 | 1939 |
| Country | Denmark | United States |
| Employees | 3029 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9B | 15.4B |
| IPO Year | N/A | 1996 |
| Metric | GMAB | RS |
|---|---|---|
| Price | $26.84 | $351.35 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 5 |
| Target Price | $39.81 | ★ $337.20 |
| AVG Volume (30 Days) | ★ 1.6M | 254.7K |
| Earning Date | 05-07-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 1.45% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 13.98 |
| Revenue | N/A | ★ $14,805,900,000.00 |
| Revenue This Year | $17.85 | $10.16 |
| Revenue Next Year | $16.04 | $0.82 |
| P/E Ratio | ★ $1.90 | $24.44 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.89 | $260.31 |
| 52 Week High | $35.43 | $365.59 |
| Indicator | GMAB | RS |
|---|---|---|
| Relative Strength Index (RSI) | 43.11 | 74.60 |
| Support Level | $24.95 | $283.82 |
| Resistance Level | $29.64 | $365.59 |
| Average True Range (ATR) | 0.57 | 9.92 |
| MACD | -0.09 | 3.80 |
| Stochastic Oscillator | 3.40 | 77.05 |
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Reliance Inc operates a network of companies providing diversified metal solutions and is the metals service center company. It distributes a full line of over 100,000 metal products, including alloy, aluminum, brass, copper, carbon steel, stainless steel, titanium and other specialty steel products. The company services more than 125,000 customers in a variety of industries, including consumer products, general manufacturing, non-residential construction, transportation, aerospace, energy, electronics and semiconductor fabrication, industrial machinery and heavy industry. It also services the auto industry, through its toll processing operations where it processes customer-owned metal for a fee.